Over the past three months I, probably like most have benefitted from the movement in small micro - cap stock that have risen heavily on increased liquidity. The next stock, despite having benefitted from a massive surge in share price back in April, that I have focused on is Ultrasis. This company is poised to secure the ever increasing Mental Health Market both at home and in the US (Several lucrative contracts already announced)through its suite of highly effective software.

The companies web address is as follows http://www.ultrasis.co.uk

I for one have gone heavily into this stock and am prepared to wait for the realisation of its potential to kick in .I would advise others to do so

DYOR

what do ppl prediction about this share the price will go?

Times article below. Cheers. B


Counselling by computer to fight depression
By Sam Lister
Hi-tech treatment is intended to ease demand on the NHS



MILLIONS of people suffering from depression, one of the biggest burdens on the NHS, will soon be able to get counselling by computer with the expansion of a revolutionary programme for GPs surgeries.
After trials on the interactive programme, which counsels users to help them to overcome depressive tendencies, an NHS trust in Wiltshire will become the first to introduce it in all primary care services.



Such is the demand for treatment for depression a condition that affects an estimated six million Britons that the therapy is to be recommended to primary care trusts nationwide in clinical guidelines published this year.

Of the 1.3 million suffering severe depression, only 10 per cent are thought to receive adequate therapy because of a reluctance to seek help and pressure on NHS resources, with patients waiting up to a year to see a counsellor.

Unlike conventional depression treatment, based on consultations with doctors and psychotherapists and regimented courses of medication, the computer counselling, called Beating the Blues, requires a single guidance session, dramatically reducing costs and pressure on staff.

Random trials have shown that the treatment which uses cognitive behaviour the- rapy (CBT) to alter outlook and mood to be as effective as, and greatly enhance, other clinical treatments. For many patients, particularly those who fear confrontation with a clinician, it has been found to be a far quicker cure.

While private surgeries and individual GPs have tested the scheme over the past year, Swindon Primary Care Trust last week became the first trust in Britain to buy licences for Beating the Blues for all 30 of its practices, at a cost of 50,000.

Take-up by other primary care trusts, which treat 95 per cent of mental health problems, is expected to rise after the publication of depression guidelines by the National Institute of Clinical Excellence (NICE), due in November.

Sir David Goldberg, the reports lead author and a strong advocate of such forms of therapy, has described the programme as one of the most important advances in the treatment of anxious depression in the last 50 years.

The economic burden of depression has risen sharply in recent years. It costs the NHS more than 1 billion a year and accounts for a further 6 billion of lost productivity while GP consultations for depression have more than doubled in the last ten years.

The new programme, which was developed at the Institute of Psychiatry in London in conjunction with Ultrasis, an IT healthcare company, works by taking sufferers through systematic steps to help them to think differently about everyday situations that trigger anxiety from running late in a traffic jam to being stood up in a bar.

Different character case studies the middle-class housewife, the elderly widow, the single parent also offer alternative insights and emotional responses, helping to illustrate, and ultimately to teach how to control, the links between negative feelings and thoughts.

For Peter Crouch, a GP at Taw Hill Medical Practice, a flagship surgery in Swindon, the arrival of the Beating the Blues course has increased capacity more than five-fold since it was introduced last year.

From August, patients served by the primary care trust will be able to attend the course of eight one-hour sessions at any time, rather than the once-weekly psychother- apy sessions now offered by surgeries. This programme has been identified as an incredibly effective way of rolling out a vital service to everyone who wants it, said Dr Crouch, an adviser to the primary care trust.

It is a programme that helps patients realise the capa- city to help themselves. Traditional forms of counselling have often fostered a dependency on the service among patients, but they should leave this feeling a crucial sense of self-control. For doctors at the Priory, the private health clinic famed for its celebrity clientele, the programmes value has been evident since its introduction nine months ago.

According to Paul McLaren, medical director of the Priory's clinic in Ticehurst, Kent, its 400 course of computerised cognitive therapy has proved an excellent complement to anti-depressant drugs and face-to-face counselling. We were very interested in looking at new ways of delivering mental health care at a cost people could afford, he said.

We wanted to be able to give people choice, and in the public sector the options to date have been very limited. Dr McLaren said that South London and Maudsley NHS Trust, where he also works as a consultant psychiatrist, planned to bring in the programme before the end of the year. Most of the NHS service is currently overwhelmed, he said.

Recent research into depression treatment found that 80 per cent of family doctors felt that they prescribed too many anti-depressants, a trend forced on them by the lack of appropriate psychological therapies or social care on the NHS. A quarter of all GPs surveyed this month rated wider access to depression treatment as one of the health services most pressing priorities.

HAUNTED BY THE BLACK DOG

An estimated 1.3 million Britons suffer from severe depression, yet only 10 per cent receive adequate therapy. A further five million people are categorised as suffering from milder conditions of mixed depression and anxiety

Depression refers to a wide range of mental health problems characterised by the loss of interest and enjoyment in ordinary things and experiences, low moods and a range of associated emotional, physical and behavioural symptoms

As the most common psychiatric disorder, depression is ranked as the fourth biggest burden on healthcare by the World Health Organisation. It is expected to worsen over the next 20 years

One in four UK women and one in ten men are likely to suffer depression serious enough to require treatment


GP consultations for depression jumped from four million to more than nine million between 1994 and 1998


http://www.timesonline.co.uk/printFriendly/0,,1-2-1071128,00.html

thanks b shame the selling is heavey then buying looks like punters wont to see revenues coming to the company also why no word from company if last week a deal was done.

Woodie,
this is a very speculative 'buy' never trust what you read trade-wise. my buys came up as sells on this one, this is not unusual especially when trades are around the middle of the spread. Where there's a buy there's a sell. activity is important and it's what we're acting upon that steers the price. (Sometimes). For me this one is worth a punt over the longterm, buy now and forget it, however it's not one i'd put my life savings on. DYOR as the saying goes. Good hunting. DM

David, I agree, the vast majority of transactions today were buys.

According to posters on AD^FN the interims will be out tomorrow or Thursday and will mention the contract win. Expect a bit more movement still to come this week.

might be wrong but interims are issued in july by company

just spoke to mike fd at company confirms results due friday or tormorrow would not give reason why they are being released 3 months early hopefully postive statement.

Woodie, it's the interim results for the first six months of the ULT's finacial year that runs August to July.

the 2 halfyear dates are jan and july the last 3 years the results to the end of jan have been issued the last day it can before the stock exchange suspends the shares these have been issued in july the results for july are issued in dec with agm in jan or feb.as these are being issued 3 months in front of last year you make your own mind up if there is good news with the results.cheers woodie

Last years interims were on the 1st May and 2002's were on 30th April so they are only a little earlier. Anyway hope they bring good news. Cheers. B

What happened to their goldfish thing that cured stomache ulcers I think ???

b sorry mate could have had my mortage on july last year,not so cofindent that these will postive as contract already leaked.heres hoping cheers woodie

wake up shareholders results out today revenues show year on year increase.

unfortuantley not keep rising

can somebody enlighten me please, I would buy these but has the turnover really increased, has that 600k licence taken other revenue away? in my head it looks like if they hadn't sold that licence, their revenue would have decreased, somebody tell me i'm wrong before the price goes up, thanks

no you are not wrong the payment has been received so increase in turnover other licence deals will come to the balance sheet this year ie the swindon health care trust which was 50000 pound stated in times newspaper. cheers woodie

thanks woodie for such a prompt response, I'm gonna put a limit on of .5 and get a grands worth, then not look at it again until april 2005 (yeah right!)

before i put my last post on this site purchased 250000 shares at 0.048,the spread was to good to miss as it stood at 10% against 30% a few days ago a few months ago cant remember who it was wanted to buy these at 30% spread advise at that time wait tell spread in your favour never be sucked in unless it is in your favour.cheers woodie

Ultrasis is well worth a look this weekend.

Excellent interims announced yesterday that resulted in 40 million shares being bought including several large T (protected trades) going through at the end of the day. It was the highest volume AIM share of the day and 14th in the overall volume leaderboard.

Ultrasis has been mentioned in the Mail and FT this morning so the momentum is likely to continue next week. The capitalisation of the company is under 4m so there is huge potential.

The MMs managed to soak up all the buys(!) and the price is still at Fridays opening - mid price 0.475p. Its likely that further buying will result in a significant rise (IMO) as happened in early February (+65%) on a similar volume. The spread is currently very tight (0.45 / 0.5), and at close you could get quotes for 0.47 to sell and 0.49 to buy. However Merrill Lynch was keeping the buy price down well below the other MMs (there are only 3 MMs trading this share) so this probably won't last.

Some risk involved (as with all small caps) so please DYOR - but potential high rewards too!

Hey

does anyone have the DAILY MAIL Article ??? Please post it if you do...cheers.